Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME

被引：0
|
作者：
Ridderstrale, M. [1 ]
Fitchett, D. [2 ]
Kis, S. Giljanovic [3 ]
Woerle, H. J. [4 ]
Mattheus, M. [4 ]
Zinman, B. [5 ]
Inzucchi, S. [6 ]
机构：
[1] Steno Diabet Ctr, Gentofte, Denmark
[2] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[3] Eli Lilly Suisse SA, Representat Off, Zagreb, Croatia
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[5] Univ Toronto, Lunenfeld Tanenbaum Res Inst, Mt Sinai Hosp, Div Endocrinol, Toronto, ON, Canada
[6] Yale Univ, Endocrinol Sect, Sch Med, New Haven, CT USA
来源：
EUROPEAN HEART JOURNAL | 2016年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5803
引用
收藏
页码：1192 / 1192
页数：1
相关论文
共 50 条
  • [41] Empagliflozin and obstructive sleep apnoea: exploratory analysis from the EMPA-REG OUTCOME trial
    Neeland, I. J.
    Eliasson, B.
    Kasai, T.
    Marx, N.
    Zinman, B.
    Inzucchi, S. E.
    Wanner, C.
    Zwiener, I.
    Wojeck, B.
    Yaggi, H.
    Johansen, O.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S463 - S464
  • [42] Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
    Coleman, R. L.
    Gray, A. M.
    Broedl, U. C.
    Fitchett, D.
    George, J. T.
    Woerle, H. -J.
    Zinman, B.
    Holman, R. R.
    DIABETOLOGIA, 2017, 60 : S522 - S522
  • [43] ARE THE CARDIOVASCULAR RISK REDUCTIONS SEEN WITH EMPAGLIFLOZIN IN THE EMPA-REG OUTCOME TRIAL EXPLAINED BY CONVENTIONAL CARDIOVASCULAR RISK FACTORS?
    Fitchett, David H.
    Coleman, Ruth L.
    Gray, Alistair
    Broedl, Uli C.
    George, Jyothis
    Woerle, Hans-Juergen
    Zinman, Bernard
    Holman, Rury R.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1809 - 1809
  • [44] EFFECTS OF EMPAGLIFLOZIN ON RENAL OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL
    Wanner, Christoph
    Levin, Adeera
    Perkovic, Vlado
    Koitka-Weber, Audrey
    Mattheus, Michaela
    von Eynatten, Maximilian
    Wheeler, David
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [45] Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
    Antonio Ceriello
    Anne Pernille Ofstad
    Isabella Zwiener
    Stefan Kaspers
    Jyothis George
    Antonio Nicolucci
    Cardiovascular Diabetology, 19
  • [46] Mediators of the Improvement in Heart Failure Outcomes With Empagliflozin in the EMPA-REG OUTCOME Trial
    Fitchett, David
    Inzucchi, Silvio E.
    Zinman, Bernard
    Wanner, Christoph
    Zannad, Faiez
    Schumacher, Martin
    Schmoor, Claudia
    Ohneberg, Kristin
    Salsali, Afshin
    George, Jyothis T.
    Hantel, Stefan
    Bluhmki, Erich
    Lachin, John M.
    CIRCULATION, 2017, 136
  • [47] Empagliflozin Reduces the Total Burden of Cardiovascular Events Including Recurrent Events in the EMPA-REG OUTCOME Trial
    Fitchett, David H.
    Inzucchi, Silvio E.
    Zinman, Bernard
    Wanner, Christoph
    Anker, Stefan D.
    Pocock, Stuart
    Kaspers, Stefan
    George, Jyothis T.
    Johansen, Odd Erik
    Jamal, Waheed
    Hantel, Stefan
    Lund, Soren S.
    CIRCULATION, 2020, 142
  • [48] Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
    Ceriello, Antonio
    Ofstad, Anne Pernille
    Zwiener, Isabella
    Kaspers, Stefan
    George, Jyothis
    Nicolucci, Antonio
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [49] Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial
    Fitchett, David
    Inzucchi, Silvio E.
    Zinman, Bernard
    Wanner, Christoph
    Schumacher, Martin
    Schmoor, Claudia
    Ohneberg, Kristin
    Ofstad, Anne Pernille
    Salsali, Afshin
    George, Jyothis T.
    Hantel, Stefan
    Bluhmki, Erich
    Lachin, John M.
    Zannad, Faiez
    ESC HEART FAILURE, 2021, 8 (06): : 4517 - 4527
  • [50] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
    Fitchett, David
    Zinman, Bernard
    Wanner, Christoph
    Lachin, John M.
    Hantel, Stefan
    Salsali, Afshin
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    EUROPEAN HEART JOURNAL, 2016, 37 (19) : 1526 - 1534
12345